|
1
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with
fluorouracil compared with fluorouracil alone as first-line
treatment for metastatic colorectal cancer: a multicentre
randomised trial. Lancet. 355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta
N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and
leucovorin for metastatic colorectal cancer. Irinotecan Study
Group. N Engl J Med. 343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G,
Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by
FOLFOX6 or the reverse sequence in advanced colorectal cancer: a
randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar
|
|
4
|
Hazama S, Nagashima A, Kondo H, Yoshida S,
Shimizu R, Araki A, Yoshino S, Okayama N, Hinoda Y and Oka M: Phase
I study of irinotecan and doxifluridine for metastatic colorectal
cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci.
101:722–727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hazama S, Mishima H, Tsunedomi R, Okuyama
Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H,
Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y,
Okayama N, Oba K, Sakamoto J and Oka M: UGT1A1*6, 1A7*3, and 1A9*22
genotypes predict severe neutropenia in FOLFIRI-treated mCRC in two
prospective studies in Japan. Cancer Sci. 104:1662–1669. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanekiyo S, Hazama S, Kondo H, Nagashima
A, Eto R, Yoshida S, Shimizu R, Araki A, Yamamoto T, Uchiyama T,
Yoshino S, Okayama N, Hinoda Y and Oka M:
UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed
phase II study of irinotecan with 5′-deoxy-5-fluorouridine
(5′-DFUR) for metastatic colorectal cancer. Anticancer Res.
33:3423–3430. 2013.PubMed/NCBI
|
|
7
|
Kawato Y, Aonuma M, Hirota Y, Kuga H and
Sato K: Intracellular roles of SN-38, a metabolite of the
camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Cancer Res. 51:4187–4191. 1991.PubMed/NCBI
|
|
8
|
Rivory LP, Bowles MR, Robert J and Pond
SM: Conversion of irinotecan (CPT-11) to its active metabolite,
7-ethyl-10-hydroxycamptothecin (SN-38), by human liver
carboxylesterase. Biochem Pharmacol. 52:1103–1111. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mathijssen RH, van Alphen RJ, Verweij J,
Loos WJ, Nooter K, Stoter G and Sparreboom A: Clinical
pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer
Res. 7:2182–2194. 2001.PubMed/NCBI
|
|
10
|
Iyer L, Das S, Janisch L, Wen M, Ramírez
J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ:
UGT1A1*28 polymorphism as a determinant of irinotecan disposition
and toxicity. Pharmacogenomics J. 2:43–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Toffoli G, Cecchin E, Corona G, Russo A,
Buonadonna A, D’Andrea M, Pasetto LM, Pessa S, Errante D, De
Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E,
Bonura S, Boccalon M, Biason P and Frustaci S: The role of
UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics
of irinotecan in patients with metastatic colorectal cancer. J Clin
Oncol. 24:3061–3068. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guillemette C, Ritter JK, Auyeung DJ,
Kessler FK and Housman DE: Structural heterogeneity at the
UDP-glucuronosyltransferase 1 locus: functional consequences of
three novel missense mutations in the human UGT1A7 gene.
Pharmacogenetics. 10:629–644. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ando Y, Saka H, Ando M, Sawa T, Muro K,
Ueoka H, Yokoyama A, Saitoh S, Shimokata K and Hasegawa Y:
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan
toxicity: a pharmacogenetic analysis. Cancer Res. 60:6921–6926.
2000.PubMed/NCBI
|
|
14
|
Ando M, Ando Y, Sekido Y, Ando M,
Shimokata K and Hasegawa Y: Genetic polymorphisms of the
UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in
Japanese cancer patients. Jpn J Cancer Res. 93:591–597. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamanaka H, Nakajima M, Katoh M, Hara Y,
Tachibana O, Yamashita J, McLeod HL and Yokoi T: A novel
polymorphism in the promoter region of human UGT1A9 gene
(UGT1A9*22) and its effects on the transcriptional activity.
Pharmacogenetics. 14:329–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sai K, Saeki M, Saito Y, Ozawa S, Katori
N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K,
Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A,
Shirao K, Yoshida T and Saijo N: UGT1A1 haplotypes associated with
reduced glucuronidation and increased serum bilirubin in
irinotecan-administered Japanese patients with cancer. Clin
Pharmacol Ther. 75:501–515. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han JY, Lim HS, Shin ES, Yoo YK, Park YH,
Lee JE, Jang IJ, Lee DH and Lee JS: Comprehensive analysis of UGT1A
polymorphisms predictive for pharmacokinetics and treatment outcome
in patients with non-small-cell lung cancer treated with irinotecan
and cisplatin. J Clin Oncol. 24:2237–2244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cecchin E, Innocenti F, D’Andrea M, Corona
G, De Mattia E, Biason P, Buonadonna A and Toffoli G: Predictive
role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their
haplotypes on the outcome of metastatic colorectal cancer patients
treated with fluorouracil, leucovorin, and irinotecan. J Clin
Oncol. 27:2457–2465. 2009. View Article : Google Scholar
|
|
19
|
Fujita K, Ando Y, Nagashima F, Yamamoto W,
Eodo H, Araki K, Kodama K, Miya T, Narabayashi M and Sasaki Y:
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is
associated with reduced activity for SN-38 in Japanese patients
with cancer. Cancer Chemother Pharmacol. 60:515–522. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roth AD, Yan P, Dietrich D, Fiocca R,
Bodoky G, Labianca R, Cunningham D, Van Cutsem E, Bosman F and
Tejpar S: Is UGT1A1*28 homozygosity the strongest predictor for
severe hematotoxicity in patients treated with 5-fluorouracil
(5-FU)-irinotecan (IRI)? Results of the PETACC 3 - EORTC 40993 -
SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in
stage II-III colon cancer (COC) patients. J Clin Oncol. 26(Suppl):
abs 4036. 2008.
|
|
21
|
Kweekel D, Guchelaar HJ and Gelderblom H:
Clinical and pharmacogenetic factors associated with irinotecan
toxicity. Cancer Treat Rev. 34:656–669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Innocenti F, Kroetz DL, Schuetz E, Dolan
ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL and Ratain MJ:
Comprehensive pharmacogenetic analysis of irinotecan neutropenia
and pharmacokinetics. J Clin Oncol. 27:2604–2614. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
UGT Alleles Nomenclature Home Page. UGT
Nomenclature Committee. June. 2005, http://www.pharmacogenomics.pha.ulaval.ca/cms/site/pharmacogenomics/ugt_alleles.
Accessed 04.01.2013
|
|
24
|
Pudil P, Novovicova J and Kittler J:
Floating search methods in feature selection. Pattern Recognition
Lett. 15:1119–1125. 1994. View Article : Google Scholar
|
|
25
|
Okuyama Y, Hazama S, Nozawa H, Kobayashi
M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K,
Sakamoto J and Mishima H: Prospective phase II study of FOLFIRI for
mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Jpn J Clin Oncol. 41:477–482. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirata K, Nagata N, Kato T, Okuyama Y,
Andoh H, Takahashi K, Oba K, Sakamoto J, Hazama S and Mishima H:
Prospective phase II trial of second-line FOLFIRI in patients with
advanced colorectal cancer including analysis of UGT1A1
polymorphisms: FLIGHT 2 study. Anticancer Res. 34:195–201.
2014.PubMed/NCBI
|
|
27
|
Wang L, Hirayasu K, Ishizawa M and
Kobayashi Y: Purification of genomic DNA from human whole blood by
isopropanol-fractionation with concentrated NaI and SDS. Nucleic
Acids Res. 22:1774–1775. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okayama N, Hamanaka Y, Suehiro Y, Hasui Y,
Nakamura J and Hinoda Y: Association of interleukin-10 promoter
single nucleotide polymorphisms-819 T/C and -592 A/C with aging. J
Gerontol A Biol Sci Med Sci. 60:1525–1529. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barrett JC, Fry B, Maller J and Daly MJ:
Haploview: analysis and visualization of LD and haplotype maps.
Bioinformatics. 21:263–265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
The R project website. http://www.r-project.org/.
|
|
31
|
Smith NF, Figg WD and Sparreboom A:
Pharmacogenetics of irinotecan metabolism and transport: an update.
Toxicol In Vitro. 20:163–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lamas MJ, Duran G, Balboa E, Bernardez B,
Candamio S, Vidal Y, Mosquera A, Giraldez JM, Lopez R, Carracedo A
and Barros F: The value of genetic polymorphisms to predict
toxicity in metastatic colorectal patients with irinotecan-based
regimens. Cancer Chemother Pharmacol. 69:1591–1599. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Araki K, Fujita K, Ando Y, Nagashima F,
Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M and Sasaki Y:
Pharmacogenetic impact of polymorphisms in the coding region of the
UGT1A1 gene on SN-38 glucuronidation in Japanese patients with
cancer. Cancer Sci. 97:1255–1259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Satoh T, Ura T, Yamada Y, Yamazaki K,
Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y,
Koizumi W, Kakeji Y, Ishizuka N, Hyodo I and Sakata Y:
Genotype-directed, dose-finding study of irinotecan in cancer
patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci.
102:1868–1873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Innocenti F, Undevia SD, Iyer L, Chen PX,
Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM,
Vokes EE and Ratain MJ: Genetic variants in the
UDP-glucuronosyltransferase 1A1 gene predict the risk of severe
neutropenia of irinotecan. J Clin Oncol. 22:1382–1388. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Innocenti F, Liu W, Chen P, Desai AA, Das
S and Ratain MJ: Haplotypes of variants in the
UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet
Genomics. 15:295–301. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Massacesi C, Terrazzino S, Marcucci F,
Rocchi MB, Lippe P, Bisonni R, Lombardo M, Pilone A, Mattioli R and
Leon A: Uridine diphosphate glucuronosyl transferase 1A1 promoter
polymorphism predicts the risk of gastrointestinal toxicity and
fatigue induced by irinotecan-based chemotherapy. Cancer.
106:1007–1016. 2006. View Article : Google Scholar
|
|
38
|
Minami H, Sai K, Saeki M, Saito Y, Ozawa
S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K,
Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A and Saijo N:
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic
polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet
Genomics. 17:497–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saito Y, Sai K, Maekawa K, Kaniwa N,
Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y,
Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N and
Sawada J: Close association of UGT1A9 IVS1+399C>T with
UGT1A1*28, *6, or *60 haplotype and its apparent influence on
7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Drug Metab Dispos. 37:272–276. 2009.PubMed/NCBI
|
|
40
|
Martinez-Balibrea E, Abad A,
Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E,
Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL
and Moreno V: UGT1A and TYMS genetic variants predict toxicity and
response of colorectal cancer patients treated with first-line
irinotecan and fluorouracil combination therapy. Br J Cancer.
103:581–589. 2010. View Article : Google Scholar
|
